COR
Cencora, Inc.
NYSE · Healthcare · Medical - Distribution · US
$330.95
−1.86%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 332.8B | 321.3B | 294.0B | 262.2B | 238.6B |
| Cost of Revenue | 320.4B | 311.2B | 285.3B | 254.4B | 231.0B |
| Gross Profit | 12.3B | 10.1B | 8.7B | 7.8B | 7.6B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 7.7B | 6.5B | 5.7B | 5.3B | 4.8B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 354.6M | — | — | — | — |
| Total Operating Expenses | 8.0B | 6.5B | 5.7B | 5.3B | 4.8B |
| Cost and Expenses | 328.4B | 317.7B | 290.9B | 259.7B | 235.8B |
| Operating Income (EBIT) | 4.3B | 3.6B | 3.0B | 2.4B | 2.8B |
| Non-Operating | |||||
| Interest Income | 66.4M | 128.2M | 91.7M | 46.7M | 21.3M |
| Interest Expense | 497.8M | 419.8M | 248.7M | 275.6M | 232.0M |
| Net Interest Income | (431.4M) | (291.5M) | (157.0M) | (228.9M) | (210.7M) |
| Other Non-Op Income/Expense | (729.6M) | (1.4B) | (1.0B) | (285.7M) | (568.6M) |
| Non-Operating Income (excl Interest) | 252.8M | 969.6M | 787.5M | 10.0M | 336.6M |
| EBT (Pre-Tax Income) | 3.6B | 2.3B | 2.0B | 2.2B | 2.2B |
| Income Tax Expense | 967.3M | 690.5M | 484.7M | 428.3M | 516.5M |
| Bottom Line | |||||
| Net Income | 2.6B | 1.6B | 1.5B | 1.7B | 1.7B |
| Earnings from Cont. Ops | 2.6B | 1.6B | 1.5B | 1.7B | 1.7B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 2.6B | 1.6B | 1.5B | 1.7B | 1.7B |
| Per Share | |||||
| Basic EPS | $13.52 | $8.02 | $7.60 | $8.62 | $8.15 |
| Diluted EPS | $13.46 | $7.96 | $7.53 | $8.53 | $8.04 |
| Revenue Per Share | $1,722.89 | $1,657.89 | $1,480.88 | $1,281.45 | $1,144.46 |
| Shares | |||||
| Basic Shares Outstanding | 193.1M | 193.8M | 198.5M | 204.6M | 208.5M |
| Diluted Shares Outstanding | 193.9M | 195.2M | 200.3M | 204.6M | 211.2M |
| Profitability Metrics | |||||
| EBITDA | 5.1B | 3.7B | 3.4B | 3.4B | 3.1B |
| D&A | 1.1B | 1.1B | 1.1B | 972.4M | 697.9M |
| EBIT | 4.1B | 2.7B | 2.3B | 2.4B | 2.4B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026